Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients

BackgroundHeparin administration in COVID-19 patients is recommended by expert consensus, although evidence about dosage, duration and efficacy are limited. We aim to investigate the association between different dosages of low molecular weight heparin (LMWH) and mortality among COVID-19 hospitalize...

Full description

Bibliographic Details
Main Authors: Pasquale Paolisso, Luca Bergamaschi, Emanuela Concetta D’Angelo, Francesco Donati, Maddalena Giannella, Sara Tedeschi, Renato Pascale, Michele Bartoletti, Giulia Tesini, Mauro Biffi, Benilde Cosmi, Carmine Pizzi, Pierluigi Viale, Nazzareno Galié
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Pharmacology
Subjects:
COVID- 19
heparin
LMWH (low molecular weight heparin)
in-hospital mortality
DVT prophylaxis
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01124/full

Similar Items

Similar Items